--New Funds will Support Expanded Commercialization of the Revolutionary
Accuri C6 Flow Cytometer(R) System--
ANN ARBOR, Mich., July 8 /PRNewswire/ -- Accuri Cytometers Inc., a life sciences company developing revolutionary bench-top flow cytometer systems, today announced the completion of a $13 million Series C financing led by Fidelity Biosciences and Flagship Ventures. Current investors including Baird Venture Partners and Arboretum Ventures also participated in the financing. Accuri will use the proceeds from the Series C financing primarily to expand its commercialization activities for the Accuri C6 Flow Cytometer(R) System. Bahaa Fam, Venture Partner, Fidelity Biosciences and Harry Wilcox, Partner, Flagship Ventures, will join the company's Board of Directors.
Explicitly designed for routine use by biomedical researchers in their own labs, Accuri's flow cytometer system is a full featured bench-top cell analysis system that provides capabilities similar to industry-leading flow cytometers in a more user-friendly format and at a fraction of the cost.
"This successful Series C financing led by Fidelity Biosciences and Flagship Ventures reflects the progress we have achieved in developing and commercializing our breakthrough flow cytometer system," said Jennifer Baird, CEO of Accuri. "Our strong initial acceptance in the marketplace is now ramping up and these new resources will enable us to further expand the reach of our marketing and sales efforts. We are pleased that our existing venture investors all participated in this round, and we look forward to the contributions of our new Board members."
Accuri created its revolutionary C6 system with input from hundreds of
researchers who use flow cytometry, including many whose research has been
fettered by resource constraints in their facilities. The company teamed
with Menlo Innovations, which brought its unique, award-winning methods to
the development of
|SOURCE Accuri Cytometers Inc.|
Copyright©2008 PR Newswire.
All rights reserved